1. Scrip
  2. >>Business

Roche Looks Steady In Headwinds But Under Pressure To Deliver M&A

 
• By Andrew McConaghie

The Swiss company will see a slight decline in revenues this year as its COVID-19 sales drop off and investors are calling for a return to M&A to help spur growth.

Roche_Logo_Glass

Roche’s full year 2023 revenues look set to shrink slightly due to a hefty CHF4.5bn ($5bn) decline in COVID-19 sales compared with last year but underlying growth from new products, including a hugely successful launch of eye drug Vabysmo, should set it up for a bounce back in 2024.

Nevertheless, the Swiss pharma giant is under pressure from investors to add extra growth drivers to its pipeline and new CEO Thomas Schinecker fielded queries on its Q3 analyst

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.